Commenting on today's results Rochester Medical's CEO and President Anthony J. Conway said, "The excellent 37% constant currency growth in Direct Sales for the quarter was in large part due to the Laprolan acquisition reinforced by continued solid growth in Direct Sales of 24% in the combined U.S. and U.K. markets where we have a sales force presence. The growth was partially offset by a decline in Direct Sales in other parts of the world due to timing of orders and shipments.
"I want to thank our Laprolan employees for their spirit of co-operation and excitement as they have become an important part of the Rochester Medical Team. Now, with significant presence in the U.K., The Netherlands, and the United States, and with sales in countries throughout the world, we are truly becoming a recognized global leader in our field."
Conway concluded, "By fiscal year end we expect to be operating profitably. Looking ahead, we are strongly focused on growing the top line, flattening costs, and generating profits."
Acquisition of Laprolan B.V.On April 7, 2011, Rochester Medical announced the completed acquisition of Laprolan B.V., the former Medical Supplies Division and wholly owned subsidiary of Fornix BioSciences N.V. Under the terms of the purchase agreement the purchase is deemed retroactive to January 1, 2011. The final purchase price for Laprolan B.V., was $14,878,125 net of interest paid.
Agreement with Teleflex IncorporatedRochester Medical today announced an exclusive agreement with Teleflex Incorporated whereby they will market and sell Rochester Medical's Strata-NF Anti-
|SOURCE Rochester Medical Corporation|
Copyright©2010 PR Newswire.
All rights reserved